Literature DB >> 26909002

Do SSRI Antidepressants Increase The Risk of Extrapyramidal Side Effects In Patients Taking Antipsychotics?

Matthew Allsbrook, Brant E Fries, Kristina L Szafara, Randolph E Regal.   

Abstract

PURPOSE: Among antidepressants, selective serotonin reup-take inhibitors (SSRIs) have enjoyed great popularity among clinicians as well as generally wide acceptance and tolerance among patients. A potentially overlooked side effect of SSRIs is the occasional occurrence of extrapyramidal symptoms (EPS), which could be a concern when SSRIs are used with antipsychotics. This study was designed to explore the possible association between SSRI antidepressant use and the incidence of EPS side effects in patients who take concomitant antipsychotic medications.
METHODS: The University of Michigan conducted a study at the four Michigan state mental health hospitals between May 2010 and October 2010. The Michigan Public Health Institute collected data using the InterRAI Mental Health Assessment (InterRAI MH). The present study is a retrospective cohort analysis of the cross-sectional data that were collected. Within these institutions, 693 residents were using antipsychotics. We measured the observed frequency of seven EPS recorded in the InterRAI MH within three groups of patients: 1) those on antipsychotic drugs who were taking an SSRI antidepressant; 2) those on antipsychotic drugs who were not taking an antidepressant; and 3) those on antipsychotic drugs who were taking a non-SSRI antidepressant. Differences in the prevalence of EPS were tested using one-way analysis of variance.
RESULTS: There were no significant differences in the observed EPS frequencies among the three groups (F 2,18 = 0.01; P < 0.9901).
CONCLUSION: In this study, SSRIs did not appear to potentiate the occurrence of EPS in patients using antipsychotics.

Entities:  

Keywords:  SSRIs; akathisia; antidepressant; antipsychotics; extrapyramidal side effects; movement disorder; neuroleptics

Year:  2016        PMID: 26909002      PMCID: PMC4745639     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  10 in total

1.  SSRI Antidepressant Medications: Adverse Effects and Tolerability.

Authors:  James M. Ferguson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-02

Review 2.  Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.

Authors:  Andrew J Bradley; Alan J Lenox-Smith
Journal:  J Psychopharmacol       Date:  2013-07-05       Impact factor: 4.153

Review 3.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

Review 4.  SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.

Authors:  R M Lane
Journal:  J Psychopharmacol       Date:  1998       Impact factor: 4.153

Review 5.  Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.

Authors:  Subramoniam Madhusoodanan; Lada Alexeenko; Renata Sanders; Ronald Brenner
Journal:  Ann Clin Psychiatry       Date:  2010-08       Impact factor: 1.567

Review 6.  Extrapyramidal Reactions Associated with Serotonergic Antidepressants.

Authors:  Jessica M Hawthorne; Charles F Caley
Journal:  Ann Pharmacother       Date:  2015-07-16       Impact factor: 3.154

7.  Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports.

Authors:  I Schillevoort; E P van Puijenbroek; A de Boer; R A C Roos; Paul A F Jansen; H G M Leufkens
Journal:  Int Clin Psychopharmacol       Date:  2002-03       Impact factor: 1.659

8.  Fluoxetine and extrapyramidal side effects.

Authors:  D M Coulter; P I Pillans
Journal:  Am J Psychiatry       Date:  1995-01       Impact factor: 18.112

Review 9.  Selective serotonin-reuptake inhibitor-induced movement disorders.

Authors:  P E Gerber; L D Lynd
Journal:  Ann Pharmacother       Date:  1998-06       Impact factor: 3.154

10.  The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.

Authors:  Christopher J L Murray; Charles Atkinson; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; David Chou; Robert Dellavalle; Goodarz Danaei; Majid Ezzati; A Fahimi; D Flaxman; Sherine Gabriel; Emmanuela Gakidou; Nicholas Kassebaum; Shahab Khatibzadeh; Stephen Lim; Steven E Lipshultz; Stephanie London; Michael F MacIntyre; A H Mokdad; A Moran; Andrew E Moran; Dariush Mozaffarian; Tasha Murphy; Moshen Naghavi; C Pope; Thomas Roberts; Joshua Salomon; David C Schwebel; Saeid Shahraz; David A Sleet; Jerry Abraham; Mohammed K Ali; Charles Atkinson; David H Bartels; Kavi Bhalla; Gretchen Birbeck; Roy Burstein; Honglei Chen; Michael H Criqui; Eric L Ding; E Ray Dorsey; Beth E Ebel; Majid Ezzati; S Flaxman; A D Flaxman; Diego Gonzalez-Medina; Bridget Grant; Holly Hagan; Howard Hoffman; Nicholas Kassebaum; Shahab Khatibzadeh; Janet L Leasher; John Lin; Steven E Lipshultz; Rafael Lozano; Yuan Lu; Leslie Mallinger; Mary M McDermott; Renata Micha; Ted R Miller; A A Mokdad; A H Mokdad; Dariush Mozaffarian; Mohsen Naghavi; K M Venkat Narayan; Saad B Omer; Pamela M Pelizzari; David Phillips; Dharani Ranganathan; Frederick P Rivara; Thomas Roberts; Uchechukwu Sampson; Ella Sanman; Amir Sapkota; David C Schwebel; Saeid Sharaz; Rupak Shivakoti; Gitanjali M Singh; David Singh; Mohammad Tavakkoli; Jeffrey A Towbin; James D Wilkinson; Azadeh Zabetian; Jerry Abraham; Mohammad K Ali; Miriam Alvardo; Charles Atkinson; Larry M Baddour; Emelia J Benjamin; Kavi Bhalla; Gretchen Birbeck; Ian Bolliger; Roy Burstein; Emily Carnahan; David Chou; Sumeet S Chugh; Aaron Cohen; K Ellicott Colson; Leslie T Cooper; William Couser; Michael H Criqui; Kaustubh C Dabhadkar; Robert P Dellavalle; Daniel Dicker; E Ray Dorsey; Herbert Duber; Beth E Ebel; Rebecca E Engell; Majid Ezzati; David T Felson; Mariel M Finucane; Seth Flaxman; A D Flaxman; Thomas Fleming; Mohammad H Forouzanfar; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Richard F Gillum; Diego Gonzalez-Medina; Richard Gosselin; Hialy R Gutierrez; Holly Hagan; Rasmus Havmoeller; Howard Hoffman; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayarman; Nicole Johns; Nicholas Kassebaum; Shahab Khatibzadeh; Qing Lan; Janet L Leasher; Stephen Lim; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Leslie Mallinger; Michele Meltzer; George A Mensah; Catherine Michaud; Ted R Miller; Charles Mock; Terrie E Moffitt; A A Mokdad; A H Mokdad; A Moran; Mohsen Naghavi; K M Venkat Narayan; Robert G Nelson; Casey Olives; Saad B Omer; Katrina Ortblad; Bart Ostro; Pamela M Pelizzari; David Phillips; Murugesan Raju; Homie Razavi; Beate Ritz; Thomas Roberts; Ralph L Sacco; Joshua Salomon; Uchechukwu Sampson; David C Schwebel; Saeid Shahraz; Kenji Shibuya; Donald Silberberg; Jasvinder A Singh; Kyle Steenland; Jennifer A Taylor; George D Thurston; Monica S Vavilala; Theo Vos; Gregory R Wagner; Martin A Weinstock; Marc G Weisskopf; Sarah Wulf
Journal:  JAMA       Date:  2013-08-14       Impact factor: 56.272

  10 in total
  1 in total

1.  Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors.

Authors:  Dania Abu-Naser; Sara Gharaibeh; Ahmad Z Al Meslamani; Qais Alefan; Renad Abunaser
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.